[HTML][HTML] PPARs in atherosclerosis: The spatial and temporal features from mechanism to druggable targets
Y Zheng, M Shao, Y Zheng, W Sun, S Qin, Z Sun… - Journal of Advanced …, 2024 - Elsevier
Background Atherosclerosis is a chronic and complex disease caused by lipid disorder,
inflammation, and other factors. It is closely related to cardiovascular diseases, the chief …
inflammation, and other factors. It is closely related to cardiovascular diseases, the chief …
Primary Prevention of Coronary and Other Cardiovascular Diseases: A Focused Review
A Higashiyama, S Kohsaka… - Journal of Atherosclerosis …, 2024 - jstage.jst.go.jp
In 2022, the Japan Atherosclerosis Society (JAS) updated its prevention guidelines, the
“Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic …
“Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic …
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial
M Harada-Shiba, MH Davdison… - … of Atherosclerosis and …, 2024 - jstage.jst.go.jp
Aims: Obicetrapib is a highly selective cholesteryl ester transfer protein (CETP) inhibitor
shown to reduce low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB) …
shown to reduce low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB) …
Blood pressure classification using the Japanese Society of Hypertension Guidelines for the Management of Hypertension and cardiovascular events among young to …
K Kuwahara, T Ohkubo, Y Inoue, T Honda… - Hypertension …, 2024 - nature.com
Abstract The Japanese Society of Hypertension updated guidelines for hypertension
management (JSH2019), changing the blood pressure (BP) classification. However …
management (JSH2019), changing the blood pressure (BP) classification. However …
Real-world clinical profile of patients prescribed evolocumab in Japan
F Sheng, AY Wang, K Miyawaki, T Tsuchiya… - Circulation …, 2024 - jstage.jst.go.jp
Background: Real-world utilization data for evolocumab, the first proprotein convertase
subtilisin/kexin type 9 (PCSK9) inhibitor to be introduced in Japan in 2016, to date are …
subtilisin/kexin type 9 (PCSK9) inhibitor to be introduced in Japan in 2016, to date are …
Risk Factors for Vulnerable Plaque Detected Using Near-Infrared Spectroscopy in Patients Receiving Statin Therapy with No History of Coronary Artery Disease
N Suzuki, T Yokoi, T Kimura, Y Ikeda… - International Heart …, 2023 - jstage.jst.go.jp
Residual risk of atherosclerosis remains high despite the use of lipid-lowering therapy with
statins. Nearinfrared spectroscopy intravascular ultrasound imaging (NIRS-IVUS) can …
statins. Nearinfrared spectroscopy intravascular ultrasound imaging (NIRS-IVUS) can …
Impact of Masticatory Performance and the Tongue-Lip Motor Function on Incident Adverse Health Events in Patients with Metabolic Disease
M Takahara, T Shiraiwa, Y Maeno… - … of Atherosclerosis and …, 2024 - jstage.jst.go.jp
Aim: The present study aimed to determine whether decreased masticatory performance
and tongue-lip motor function are associated with an increased incidence of adverse health …
and tongue-lip motor function are associated with an increased incidence of adverse health …
Relationships of the Surface Charge of Low-Density Lipoprotein (LDL) with the Serum LDL-Cholesterol and Atherosclerosis Levels in a Japanese Population: The …
K Nakamura, S Takeda, T Sakurai, S Ukawa… - … of Atherosclerosis and …, 2024 - jstage.jst.go.jp
Aim: This study investigated the associations of the surface charge of low-density lipoprotein
(LDL) with the serum LDL-cholesterol and atherosclerosis levels in a community-based …
(LDL) with the serum LDL-cholesterol and atherosclerosis levels in a community-based …
Associations between the Serum Triglyceride Level and Kidney Outcome in Patients with Chronic Kidney Disease: The Fukuoka Kidney disease Registry Study
M Seki, T Nakano, S Tanaka, H Kitamura… - … of Atherosclerosis and …, 2024 - jstage.jst.go.jp
Aims: Hypertriglyceridemia is a risk factor for chronic kidney disease (CKD). However,
whether or not it predicts the risk of CKD progression is unknown. This study evaluated the …
whether or not it predicts the risk of CKD progression is unknown. This study evaluated the …
Lipoprotein Apheresis Alleviates Treatment-Resistant Peripheral Artery Disease Despite the Normal Range of Atherogenic Lipoproteins: The LETS-PAD Study
E Ueda, Y Toya, H Wakui, K Ishiga, Y Kawai… - … of Atherosclerosis and …, 2024 - jstage.jst.go.jp
Aim: Peripheral artery disease (PAD) severely impairs patient prognosis and quality of life
(QOL). Although lipoprotein apheresis (LA) has been applied to patients with PAD and …
(QOL). Although lipoprotein apheresis (LA) has been applied to patients with PAD and …